Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Leases (2019 - 2025)

Historic Current Leases for Fortress Biotech (FBIO) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Fortress Biotech's Current Leases fell 1531.42% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 1531.42%. This contributed to the annual value of $2.6 million for FY2024, which is 396.35% up from last year.
  • Per Fortress Biotech's latest filing, its Current Leases stood at $2.1 million for Q3 2025, which was down 1531.42% from $2.1 million recorded in Q2 2025.
  • Fortress Biotech's Current Leases' 5-year high stood at $2.6 million during Q4 2024, with a 5-year trough of $1.8 million in Q1 2021.
  • Its 5-year average for Current Leases is $2.3 million, with a median of $2.3 million in 2022.
  • As far as peak fluctuations go, Fortress Biotech's Current Leases soared by 2062.46% in 2021, and later tumbled by 1699.35% in 2025.
  • Quarter analysis of 5 years shows Fortress Biotech's Current Leases stood at $2.1 million in 2021, then rose by 16.3% to $2.4 million in 2022, then grew by 3.11% to $2.5 million in 2023, then increased by 3.96% to $2.6 million in 2024, then decreased by 18.83% to $2.1 million in 2025.
  • Its Current Leases was $2.1 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.2 million in Q1 2025.